Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

European Journal of Medicinal Chemistry

Volumn 70, Issue , 2013, Pages 758-767

  Deng, Xianming ^a   Elkins, Jonathan M ^b   Zhang, Jinwei ^c   Yang, Qingkai ^d   Erazo, Tatiana ^e   Gomez, Nestor ^e   Choi, Hwan Geun ^a   Wang, Jinhua ^a   Dzamko, Nicolas ^c   Lee, Jiing Dwan ^d   Sim, Taebo ^f   Kim, Namdoo ^f   Alessi, Dario R ^c   Lizcano, Jose M ^e   Knapp, Stefan ^b   Gray, Nathanael S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e INSTITUT DE NEUROCIÈNCIES   (Spain)

^f Korea Institute of Science and Technology   (South Korea)

Author keywords

Benzo e pyrimido 5,4 b diazepine 6(11H) one; ERK5 inhibitor; Kinase selectivity

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BENZO[ E ]PYRIMIDO [5,4 BETA]DIAZEPINE 6(11 H ) ONE; BIX 02188; BIX 02189; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; LEUCINE RICH REPEAT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BIOAVAILABILITY; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STRUCTURE; IC 50; RADIOCHEMISTRY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

2-DICYCLOHEXYLPHOSPHINO-2′,4′,6′-TRIISOPROPYL-BIPHENYL; BENZO[E]PYRIMIDO-[5,4-B]DIAZEPINE-6(11H)-ONE; BIG MAP KINASE 1; BMK1; DCAMKL2; DIEA; DMA; DOUBLECORTIN AND CAM KINASE-LIKE 2; EGF; EPIDERMAL GROWTH FACTOR; ERK5; ERK5 INHIBITOR; EXTRACELLUAR-SIGNAL-REGULATED KINASE 5; HCC; HEPATOCELLULAR CARCINOMA; KINASE SELECTIVITY; LEUCINE RICH REPEAT KINASE 2; LRRK2; MAP KINASE KINASE 5; MAPK; MEK5; MITOGEN-ACTIVATED PROTEIN KINASE; MITOGEN-ACTIVATED PROTEIN KINASE 7; N,N-DIISOPROPYLETHYLAMINE; N,N-DIMETHYLACETAMIDE; PD(2)(DBA)(3); PLK; PML; POLO-LIKE KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; RIBOSOMAL S6 KINASE; RSK; SAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM-(0); X-PHOS; XVBGRTMNFNMINE-UHFFFAOYSA-N;

AZEPINES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HEK293 CELLS; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 7; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887384933     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.10.052     Document Type: Article

References (35)

1. C. Widmann, S. Gibson, M.B. Jarpe, and G.L. Johnson Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human Physiol. Rev. 79 1999 143 180 (Pubitemid 29056951)
2. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40 (Pubitemid 32225829)
3. P.A. Lochhead, R. Gilley, and S.J. Cook ERK5 and its role in tumour development Biochem. Soc. Trans. 40 2012 251 256
4. H. Song, X. Jin, and J. Lin Stat3 upregulates MEK5 expression in human breast cancer cells Oncogene 23 2004 8301 8309 (Pubitemid 39531841)
5. P.B. Mehta, B.L. Jenkins, L. McCarthy, L. Thilak, C.N. Robson, D.E. Neal, and H.Y. Leung MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion Oncogene 22 2003 1381 1389 (Pubitemid 36384600)
6. S.R. McCracken, A. Ramsay, R. Heer, M.E. Mathers, B.L. Jenkins, J. Edwards, C.N. Robson, R. Marquez, P. Cohen, and H.Y. Leung Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer Oncogene 27 2008 2978 2988 (Pubitemid 351668010)
7. K. Zen, K. Yasui, T. Nakajima, Y. Zen, Y. Gen, H. Mitsuyoshi, M. Minami, S. Mitsufuji, S. Tanaka, Y. Itoh, Y. Nakanuma, M. Taniwaki, S. Arii, T. Okanoue, and T. Yoshikawa ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry Genes Chromosomes Cancer 48 2009 109 120
8. A.K. Ramsay, S.R. McCracken, M. Soofi, J. Fleming, A.X. Yu, I. Ahmad, R. Morland, L. Machesky, C. Nixon, D.R. Edwards, R.K. Nuttall, M. Seywright, R. Marquez, E. Keller, and H.Y. Leung ERK5 signalling in prostate cancer promotes an invasive phenotype Br. J. Cancer 104 2011 664 672
9. C. Clape, V. Fritz, C. Henriquet, F. Apparailly, P.L. Fernandez, F. Iborra, C. Avances, M. Villalba, S. Culine, and L. Fajas miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice PloS One 4 2009 e7542
10. S. Noguchi, T. Mori, Y. Hoshino, K. Maruo, N. Yamada, Y. Kitade, T. Naoe, and Y. Akao MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells Cancer Lett. 307 2011 211 220
11. A.F. Ibrahim, U. Weirauch, M. Thomas, A. Grunweller, R.K. Hartmann, and A. Aigner MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma Cancer Res. 71 2011 5214 5224
12. J.D. Lee, R.J. Ulevitch, and J. Han Primary structure of BMK1: a new mammalian map kinase Biochem. Biophys. Res. Commun. 213 1995 715 724
13. G. Zhou, Z.Q. Bao, and J.E. Dixon Components of a new human protein kinase signal transduction pathway J. Biol. Chem. 270 1995 12665 12669
14. R.J. Tatake, M.M. O'Neill, C.A. Kennedy, A.L. Wayne, S. Jakes, D. Wu, S.Z. Kugler Jr., M.A. Kashem, P. Kaplita, and R.J. Snow Identification of pharmacological inhibitors of the MEK5/ERK5 pathway Biochem. Biophys. Res. Commun. 377 2008 120 125
15. P. Lenart, M. Petronczki, M. Steegmaier, B. Di Fiore, J.J. Lipp, M. Hoffmann, W.J. Rettig, N. Kraut, and J.M. Peters The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 17 2007 304 315
16. M. Steegmaier, M. Hoffmann, A. Baum, P. Lenart, M. Petronczki, M. Krssak, U. Gurtler, P. Garin-Chesa, S. Lieb, J. Quant, M. Grauert, G.R. Adolf, N. Kraut, J.M. Peters, and W.J. Rettig BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr. Biol. 17 2007 316 322 (Pubitemid 46241881)
17. G.P. Sapkota, L. Cummings, F.S. Newell, C. Armstrong, J. Bain, M. Frodin, M. Grauert, M. Hoffmann, G. Schnapp, M. Steegmaier, P. Cohen, and D.R. Alessi BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo Biochem. J. 401 2007 29 38 (Pubitemid 46114597)
18. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, R. Faraoni, M. Floyd, J.P. Hunt, D.J. Lockhart, Z.V. Milanov, M.J. Morrison, G. Pallares, H.K. Patel, S. Pritchard, L.M. Wodicka, and P.P. Zarrinkar A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
19. X. Deng, Q. Yang, N. Kwiatkowski, T. Sim, U. McDermott, J.E. Settleman, J.D. Lee, and N.S. Gray Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin- 6(11H)-one as a potent and selective inhibitor of big MAP kinase 1 ACS Med. Chem. Lett. 2 2011 195 200
20. Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M.P. Patricelli, J.R. Yates 3rd, N.S. Gray, and J.D. Lee Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein Cancer Cell 18 2010 258 267
21. X. Deng, N. Dzamko, A. Prescott, P. Davies, Q. Liu, Q. Yang, J.D. Lee, M.P. Patricelli, T.K. Nomanbhoy, D.R. Alessi, and N.S. Gray Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 2011 203 205
22. J. Abe, M. Kusuhara, R.J. Ulevitch, B.C. Berk, and J.D. Lee Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase J. Biol. Chem. 271 1996 16586 16590 (Pubitemid 26239014)
23. J.C. Dächsel, and M.J. Farrer LRRK2 and Parkinson disease Arch. Neurol. 67 2010 542 547
24. R.G. Lowery, and J. Majer Assay Method for Group Transfer Reactions, in, USA 2008 44 Cont.-in-part of U.S. Ser. No.353,500
25. N. Dzamko, M. Deak, F. Hentati, A.D. Reith, A.R. Prescott, D.R. Alessi, and R.J. Nichols Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization Biochem. J. 430 2010 405 413
26. N. Kwiatkowski, X. Deng, J. Wang, L. Tan, F. Villa, S. Santaguida, H.C. Huang, T. Mitchison, A. Musacchio, and N. Gray Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen ACS Chem. Biol. 7 2012 185 196
27. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
28. M.P. Patricelli, A.K. Szardenings, M. Liyanage, T.K. Nomanbhoy, M. Wu, H. Weissig, A. Aban, D. Chun, S. Tanner, and J.W. Kozarich Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 46 2007 350 358 (Pubitemid 46105428)
29. Glide, version 3.5. http://www.schrodinger.com.
30. B.K. Gilsbach, F.Y. Ho, I.R. Vetter, P.J. van Haastert, A. Wittinghofer, and A. Kortholt Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations Proc. Natl. Acad. Sci. USA 109 2012 10322 10327
31. N. Kwiatkowski, N. Jelluma, P. Filippakopoulos, M. Soundararajan, M.S. Manak, M. Kwon, H.G. Choi, T. Sim, Q.L. Deveraux, S. Rottmann, D. Pellman, J.V. Shah, G.J. Kops, S. Knapp, and N.S. Gray Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nat. Chem. Biol. 6 2010 359 368
32. J.M. Elkins, J. Wang, X. Deng, M.J. Pattison, J.S.C. Arthur, T. Erazo, N. Gomez, J.M. Lizcano, N.S. Gray, and S. Knapp X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor J. Med. Chem. 56 2013 4413 4421
33. A. Rodriguez-Asiain, G. Ruiz-Babot, W. Romero, R. Cubi, T. Erazo, R.M. Biondi, J.R. Bayascas, J. Aguilera, N. Gomez, C. Gil, E. Claro, and J.M. Lizcano Brain specific kinase-1 BRSK1/SAD-B associates with lipid rafts: modulation of kinase activity by lipid environment Biochim. Biophys. Acta 1811 2011 1124 1135
34. J.M. Lizcano, M. Deak, N. Morrice, A. Kieloch, C.J. Hastie, L. Dong, M. Schutkowski, U. Reimer, and D.R. Alessi Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo J. Biol. Chem. 277 2002 27839 27849 (Pubitemid 34966729)
35. Y. Durocher, S. Perret, and A. Kamen High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells Nucleic Acids Res. 30 2002 E9